Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 63

    1.

    Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.

    Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T.

    J Gastroenterol. 2012 May;47(5):577-85. Epub 2012 Jan 11.

    PMID:
    22231575
    [PubMed - in process]
    2.

    Risk factors of early re-bleeding and mortality in patients with ruptured gastric varices and concomitant hepatocellular carcinoma.

    Chang CJ, Hou MC, Liao WC, Lee FY, Lin HC, Lee SD.

    J Gastroenterol. 2012 May;47(5):531-9. Epub 2012 Jan 6.

    PMID:
    22223176
    [PubMed - in process]
    3.

    Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.

    Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K.

    J Gastroenterol. 2012 Apr;47(4):477-85. Epub 2011 Dec 27.

    PMID:
    22200940
    [PubMed - in process]
    4.

    Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1.

    Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, Hisamochi A, Torimura T, Sata M; Autoimmune Hepatitis Study Group.

    J Gastroenterol. 2012 May;47(5):569-76. Epub 2011 Dec 21.

    PMID:
    22187167
    [PubMed - in process]
    5.

    Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.

    Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S.

    J Gastroenterol. 2012 Mar;47(3):343-6. Epub 2011 Dec 21.

    PMID:
    22183859
    [PubMed - in process]
    6.

    Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.

    Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab.

    J Gastroenterol. 2012 May;47(5):561-8. Epub 2011 Dec 15.

    PMID:
    22170417
    [PubMed - in process]
    7.

    Error occurred: cannot get document summary

    PMID:
    22170415

    8.

    Loss of autophagy promotes murine acetaminophen hepatotoxicity.

    Igusa Y, Yamashina S, Izumi K, Inami Y, Fukada H, Komatsu M, Tanaka K, Ikejima K, Watanabe S.

    J Gastroenterol. 2012 Apr;47(4):433-43. Epub 2011 Nov 29.

    PMID:
    22124574
    [PubMed - in process]
    9.

    Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.

    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T.

    J Gastroenterol. 2012 Apr;47(4):444-51. Epub 2011 Nov 23.

    PMID:
    22105231
    [PubMed - in process]
    10.

    Splenectomy enhances the anti-fibrotic effect of bone marrow cell infusion and improves liver function in cirrhotic mice and patients.

    Iwamoto T, Terai S, Mizunaga Y, Yamamoto N, Omori K, Uchida K, Yamasaki T, Fujii Y, Nishina H, Sakaida I.

    J Gastroenterol. 2012 Mar;47(3):300-12. Epub 2011 Nov 9.

    PMID:
    22065159
    [PubMed - in process]
    11.

    Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.

    Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F, Miyake Y, Takaki A, Yamamoto K.

    J Gastroenterol. 2012 Apr;47(4):421-6. Epub 2011 Nov 3.

    PMID:
    22048256
    [PubMed - in process]
    12.

    The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.

    Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.

    J Gastroenterol. 2012 Mar;47(3):313-20. Epub 2011 Oct 25.

    PMID:
    22038555
    [PubMed - in process]
    13.

    Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.

    Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Takeshima F, Nakao K.

    J Gastroenterol. 2012 Feb;47(2):195-202. Epub 2011 Oct 25.

    PMID:
    22038554
    [PubMed - in process]
    14.

    Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

    Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S.

    J Gastroenterol. 2011 Oct 6. [Epub ahead of print]

    PMID:
    21976133
    [PubMed - as supplied by publisher]
    15.

    Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.

    Hidaka H, Nakazawa T, Shibuya A, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Koizumi W.

    J Gastroenterol. 2011 Nov;46(11):1316-23. Epub 2011 Aug 18.

    PMID:
    21850387
    [PubMed - indexed for MEDLINE]
    16.

    Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.

    Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y.

    J Gastroenterol. 2011 Dec;46(12):1418-26. Epub 2011 Aug 16.

    PMID:
    21845378
    [PubMed - indexed for MEDLINE]
    17.

    Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

    Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S.

    J Gastroenterol. 2011 Oct;46(10):1230-7. Epub 2011 Jul 13.

    PMID:
    21748549
    [PubMed - indexed for MEDLINE]
    18.

    Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma.

    Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M, Sakamoto A.

    J Gastroenterol. 2011 Oct;46(10):1219-29. Epub 2011 Jul 9.

    PMID:
    21744129
    [PubMed - indexed for MEDLINE]
    19.

    Liver functional volumetry for portal vein embolization using a newly developed 99mTc-galactosyl human serum albumin scintigraphy SPECT-computed tomography fusion system.

    Beppu T, Hayashi H, Okabe H, Masuda T, Mima K, Otao R, Chikamoto A, Doi K, Ishiko T, Takamori H, Yoshida M, Shiraishi S, Yamashita Y, Baba H.

    J Gastroenterol. 2011 Jul;46(7):938-43. Epub 2011 Apr 27.

    PMID:
    21523415
    [PubMed - indexed for MEDLINE]
    20.

    Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen.

    Murakami K, Takahashi R, Ono M, Watanabe K, Okimoto T, Kodama M, Abe D, Kimura M, Fujioka T.

    J Gastroenterol. 2011 Sep;46(9):1120-6. Epub 2011 Jun 8.

    PMID:
    21656014
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk